The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant potential in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to offer a more substantial loss in body